2023 Year in Review from Verana Health’s CEO
Author:
Sujay Jadhav, CEO
As 2023 comes to a close, I’d like to reflect not only on a year of growth at Verana Health, but a year of innovation in our core therapeutic areas of ophthalmology, neurology and urology.
From the approval of the first two therapies in history for treatment of geographic atrophy and approval of enzalutamide – the first and only androgen receptor signaling inhibitor approved for the treatment of patients with early stage prostate cancer – to promising clinical trial results for improved dosing of subcutaneous ocrelizumab for patients with multiple sclerosis. This has been a year of innovation in the industry, and a year of renewed hope for patients.
Verana Health experienced a level of innovation this year, which I believe turned a corner in helping unlock real-world data (RWD) for more use cases and more clients to further innovation and get the right therapies to the right patients, faster.
Here are some of our key highlights from 2023:
Delivering Data on Demand
After many requests, we began delivering our 14 quality datasets, Qdata, to clients directly for use via AWS Data Exchange. This platform allows clients to access a data as a service offering with data refreshes approximately every three weeks. Not only can our clients track rolling market share and brand switching, but they are able to understand patient outcomes data that are not available in most other RWD sources in near real-time.
Partnering with Clinicians to Improve Quality of Care
In Q1 of 2023, we submitted data to the CMS Merit-based Incentive Payment System (MIPS) for the 2022 reporting year on behalf of nearly 3,000 participating clinicians in the American Academy of Ophthalmology IRISⓇ Registry (Intelligent Research in Sight) and the American Academy of Neurology Axon Registry®. The fact that so many practices chose to submit their data to Verana Health for MIPS reporting, highlights the trust they have in us to deliver quality measures and dashboards that will help improve patient care. We look forward to supporting practices for 2023 submissions.
Powering Site Selection
In addition to the availability of our 14 Qdata modules across ophthalmology, neurology and urology, we launched an exciting new platform for study sponsors and contract research organizations (CROs), called VeraSite. VeraSite is a new subscription-based platform that offers users a fast and secure way to identify participating practices and patient populations matched to study protocols to power clinical trial site selection. Verana Health has supported site and patient selection for many clinical trials to date, but it was previously delivered in a single report. Now, clients can access it on demand to inform their trial strategy as it evolves. The evolution from a single report to 24/7 access is part of what makes this a year of innovation.
Linking New Data
Our most recent partnership with Foundation Fighting Blindness enables us to link de-identified genomics and patient-reported data with de-identified ophthalmology data to support clinical research surrounding patients with inherited retinal diseases (IRDs). This is an exciting step to help support clients who are researching treatments for the roughly 5 million people worldwide expected to be affected by IRDs.
Supporting the Food and Drug Administration
The Food and Drug Administration recently awarded the American Academy of Ophthalmology and Verana Health funding to support research in pediatric cataract surgery. Treating cataracts is more urgent in infants than adults because the condition can cause blindness. This study will add more RWD on the safety and effectiveness of intraocular lenses implanted in the pediatric population. We look forward to sharing the results of our team’s work in 2024.
Unique Opportunity to Improve Patients’ Lives
Verana Health is reimagining what it means to unlock the 80% of healthcare data that remains unstructured and make it meaningful at scale. We truly have a unique opportunity to deliver patient outcomes data at scale to help get the best therapies in the hands of clinicians and transform patients’ lives.
This work isn’t easy, nor is it linear, but we have an incredible opportunity to advance trials and treatments in the coming years. I commend our talented team that brings this quality data to life every day, and asks tough questions as we collaborate to find answers to these complicated research questions. I’d also like to thank all of our clients, partners, investors, and of course, our medical society partners and their members, for believing in Verana Health and supporting us through this year of growth. We look forward to our continued partnerships in 2024.
To learn how to join us on our journey in unlocking RWD to improve patients’ lives, visit: www.veranahealth.com
Let's Accelerate Research Together
To learn more about Verana Health, please fill out the information below and our team will follow up with you as soon as possible.
